NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). It has become the standard of care for all patients with newly diagnosed chronic-phase CML based on its successful induction of durable responses in most patients. However, its use is compl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Natl Compr Canc Netw
Asıl Yazarlar: O’Brien, Susan, Berman, Ellin, Moore, Joseph O., Pinilla-Ibarz, Javier, Radich, Jerald P., Shami, Paul J., Smith, B. Douglas, Snyder, David S., Sundar, Hema M., Talpaz, Moshe, Wetzler, Meir
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4234100/
https://ncbi.nlm.nih.gov/pubmed/21335443
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller